Addition of history of intussusception as a contraindication for rotavirus vaccination

Morbidity and Mortality Weekly Report

Volumn 60, Issue 41, 2011, Pages 1427-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; RIX4414 VACCINE; ROTAVIRUS VACCINE;

DRUG CONTRAINDICATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; INTUSSUSCEPTION; NOTE; RISK; ROTAVIRUS INFECTION; UNITED STATES;

DRUG LABELING; HUMANS; INFANT; INTUSSUSCEPTION; RISK; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES, ATTENUATED;

EID: 84857117588     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. Food and Drug Administration. Product-approval information-licensing action [package insert]. Rotarix (rotavirus vaccine, live, oral), GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedpro ducts/ucm133539.pdf. Accessed October 17, 2011.
2. Food and Drug Administration. Product-approval information-licensing action [package insert] RotaTeq (rotavirus vaccine, live, oral, pentavalent), Merck & Co. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedpro ducts/ucm142288.pdf. Accessed October 17, 2011.
3. CDC. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009;58(No. RR-2).
4. Cortese M. Estimates of benefits and potential risks of rotavirus vaccination in the United States. Presented at the meeting of the Advisory Committee on Immunization Practices, Atlanta, GA; October 28, 2010. Available at http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/12-3-ro ta-estbenefitsrisks.pdf. Accessed October 17, 2011.
5. CDC. Statement regarding Rotarix and RotaTeq rotavirus vaccines and intussusception. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/vaccines/vpd-vac/rotavirus/intussusception-studies-ac ip.htm. Accessed October 17, 2011.
6. CDC. Monitoring of intussusception after RotaTeq vaccination 2011. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at http://www.cdc.gov/vaccinesafety/vaccines/rotateq_intussusception.html. Accessed October 17, 2011.
7. CDC. Updated vaccine label for Rotarix: questions and answers for health-care professionals. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-label-hcp.htm. Accessed October 17, 2011.
8. Food and Drug Administration. Information on Rotarix-labeling revision pertaining to intussusception. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2010. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm2 26690.htm. Accessed October 17, 2011.
9. Daneman A, Alton DJ, Lobo E, Gravett J, Kim P, Ein SH. Patterns of recurrence of intussusception in children: a 17-year review. Pediatr Radiol 1998;28:913-9.
10. CDC. Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR 2010;59:687-8.